Low PE stock below Rs 5: Don’t miss action in this micro-cap stock that has announced Rights Issue!

Kiran Shroff
/ Categories: Trending, Mindshare
Low PE stock below Rs 5: Don’t miss action in this micro-cap stock that has announced Rights Issue!

The shares of the company saw a spurt in volume by more than 2.07 times on BSE.

On Thursday, shares of Earum Pharmaceuticals zoomed 6.53 per cent to Rs 2.61 per share from its previous closing of Rs 2.45. The stock has a 52-week high of Rs 8.30 and a 52-week low of Rs 1.94.   

Earum Pharmaceuticals informed that the company has approved the rights issue. The eligibility of shareholders entitled to the issuance of 4 (four) fully paid-up equity shares of the company having a face value of Rs 2 (rupees two only) each for every 1 (one) equity share held by the eligible existing equity shareholder in the company on rights basis (‘Rights Issue’).  

Earum Pharmaceuticals Limited produces and distributes pharmaceutical products. The Company offers tablets, capsules, ointments, creams, gels, powders and syrup. Earum Pharmaceuticals markets its products globally.  

Earum Pharmaceuticals has a market cap of Rs 15.30 crore. The company reported positive numbers in its both Quarterly Results and annual results. In Q3FY23, the net profit zoomed 44.22 per cent compared to Q2FY22. The company has reduced its debt in FY22-23 and the current debt of the company is 8.74 crore as of today.  

The shares of the company saw a spurt in volume by more than 2.07 times on BSE. Investors should keep an eye on this micro-cap pharmaceutical company’s stock.   

Rate this article:
3.8

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary29-Sep, 2023

Mindshare30-Sep, 2023

Mindshare30-Sep, 2023

Multibaggers30-Sep, 2023

Penny Stocks30-Sep, 2023

Knowledge

General26-Sep, 2023

Technical25-Sep, 2023

Technical24-Sep, 2023

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Investment in securities market are subject to market risks.Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.